About this item:
185 Views | 220 Downloads
Author Notes:
Xinsheng Zhang: AIDS Vaccine Design and Development Laboratory, International AIDS Vaccine Initiative (IAVI), Brooklyn Army Terminal, 140 58th Street, Building A, 8th Floor, Unit 8J, Brooklyn, NY 11220, USA. Tel.: + 1 646 381 8037; fax: + 1 718 765 1870. xzhang@iavi.org
The authors are grateful for Emmanuel Cormier, Laura Sharpe and Brendan McAtarsney for serum sample management.
We also thank Wayne Koff, Rick King, Josephine Cox and Beth Rasmussen for helpful suggestions and advice; and acknowledge Heather Arendt and Joanne DeStefano for critical reading of the manuscript.
The authors also thank Shinji Ohno and Makoto Takeda from Kyushu University for providing the 2F4 mouse monoclonal antibody.
Subjects:
Research Funding:
IAVI's work is made possible by generous support from many donors including: the Bill & Melinda Gates Foundation; the Ministry of Foreign Affairs of Denmark; Irish Aid; the Ministry of Finance of Japan; the Ministry of Foreign Affairs of the Netherlands; the Norwegian Agency for Development Cooperation (NORAD); the United Kingdom Department for International Development (DFID), and the United States Agency for International Development (USAID).
This study is made possible by the generous support of the American people through USAID and is supported by the Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD).
Keywords:
- Science & Technology
- Life Sciences & Biomedicine
- Virology
- Canine distemper virus
- Measles virus
- Plaque reduction neutralization test
- Neutralizing antibody
- Hemagglutinin
- Pre-existing immunity
- Cross-neutralization
- MEASLES-VIRUS
- IMMUNOLOGICAL RELATIONSHIPS
- IMMUNE-RESPONSE
- LIVE MEASLES
- VACCINE
- ANTIBODIES
- OUTBREAK
- INFECTIONS
- MONKEYS
- FUSION
Canine distemper virus neutralization activity is low in human serum and it is sensitive to an amino acid substitution in the hemagglutinin protein
Abstract:
Copyright information:
© 2015 Elsevier Inc. All rights reserved.
